Clinical Trials

NRG Oncology

IRB
Details
Info
24-005
NRGBR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
 
Cookie Disclaimer: By using or otherwise accessing the website, you agree to that this website uses cookies and similar technologies, including those provided by vendors, for various purposes, such as to support website performance, features, and analytics (for example, Google Analytics). These cookies may process data such as IP addresses, including for them to function properly. Cookie vary across the website, including per webpage. For more information, see the Website Privacy Policy. Use or other access to this website is subject to the Website Terms and Conditions.